← All trials
NCT05266768
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2022
- Primary completion
- Feb 28, 2024
- Completion date
- Feb 28, 2024
- First posted
- Mar 4, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Collaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.